학술논문
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
Document Type
Academic Journal
Author
Askari E; Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Moghadam SZ; Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Wild D; ENETS Center of Excellence, Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.; Delpassand E; Department of Clinical Nuclear Medicine, Excel Diagnostics Imaging Clinic, Houston, Texas.; Baldari S; Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and of Morpho-Functional Imaging, University of Messina, Messina, Italy.; Nilica B; Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.; Hartrampf PE; Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.; Kong G; Sir Peter MacCallum Department of Oncology and Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Grana CM; Division of Nuclear Medicine, European Institute of Oncology, IRCCS, Milan, Italy.; Alexander Walter M; Nuclear Medicine and Molecular Division, Geneva Medical Hospital, Geneva, Switzerland.; Capoccetti F; UOC Nuclear Medicine-PET Center-Single Regional Center for Radiometabolic Therapy, Department of Radiological Diagnosis and Services, ASUR Marche Area Vasta 3, Macerata, Italy.; Kasi PM; Meyer Cancer Center and Englander Institute of Precision Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York; and.; Strosberg J; Neuroendocrine Tumor Division, Gastrointestinal Department, Moffitt Cancer Center, Tampa, Florida jonathan.strosberg@moffitt.org.
Source
Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0430303 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-5675 (Electronic) Linking ISSN: 00914916 NLM ISO Abbreviation: J Nucl Med Technol Subsets: MEDLINE
Subject
Language
English
Abstract
Merkel cell carcinoma is a rare, aggressive skin malignancy, also known as neuroendocrine carcinoma of the skin, with high rates of recurrence and distant metastasis. In refractory metastatic Merkel cell carcinoma (mMCC), besides immunotherapy, chemotherapy, and radiation, peptide receptor radionuclide therapy (PRRT) may be a viable option since this type of tumor can express somatostatin receptors. Methods: We performed a comprehensive review of the literature to evaluate the efficacy of PRRT in mMCC patients. Results: Thirty-seven patients with mMCC received PRRT (1-5 cycles) with 177 Lu- or 90 Y-labeled somatostatin analogs (cumulative activity, 1.5-30 GBq). Radiographic response was available for 19 of 28 patients who received PRRT alone. Six (31.6%) of 19 patients showed objective responses, from partial to complete, and no severe adverse events were reported. Conclusion: Our analysis supports the use of PRRT in mMCC with sufficient somatostatin receptor uptake, although the quality of the available evidence is low. Prospective clinical trials are already in development and have started accruing in some parts of the world.
(© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)
(© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)